Abstract
Purpose. Telomerase is a ribonucleoprotein that extends telomeres at the ends of chromosome. Increased telomerase activity is associated with cellular immortality. The currently available assay for telomerase, i.e., telomeric repeat amplification protocol (TRAP), consists of 2 steps: (a) telomerase-mediated extension of an oligonucleotide primer by the enzyme-containing extracts of cells and tissues, and (b) amplification of the telomerase-extended primer products by polymerase chain reaction (PCR) and detection of the PCR products. It is generally accepted that the current TRAP assay lacks quantitative precision. The present study was to develop a quantitative telomerase assay with greater precision and sensitivity.
Methods. This new method used the primer extension method as in TRAP, plus the following modifications: (a) used a lysis buffer that yielded complete lysis of nuclei; (b) removal of PCR inhibitors by phenol/chloroform extraction after primer extension; and (c) used primers for the internal standard that were designed to reduce their competition with the telomerase products for PCR.
Results. The modified method showed a good correlation (r2 = 0.99, P < 0.001) between telomerase amount (expressed as total protein in cell lysate) and its activity (expressed as telomerase products). Compared to the conventional TRAP, the new method (a) was more sensitive (average of 5.5-fold in cultured cancer cells and >5.9-fold in patient tumors), (b) had a lower inter- and intra-day variability (>3-fold), and (c) showed a 2 to 4-fold broader range of linearity in the standard curve. The higher assay sensitivity further enabled the use of a nonradioactive method, i.e., ethidium bromide staining of DNA, to detect the TRAP products, as opposed to the use of radioactive nucleotide and the more labor-intensive autoradiography mandated by the conventional TRAP.
Conclusion. We report here a quantitative assay for telomerase activity in cultured human cancer cells and patient tumors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
V. Urquidi, D. Tarin, and S. Goodison. Role of telomerase in cell senescence and oncogenesis. Ann. Rev. Med. 51:65-79 (2000).
W. Fu, J. G. Begley, M. W. Killen, and M. P. Mattson. Antiapoptosis role of telomerase in pheochromocytoma cells. J. Biol. Chem. 274:7264-7271 (1999).
C. I. Nugent, G. Bosco, L. O. Ross, S. K. Evans, A. P. Salinger, J. K. Moore, K. E. Haber, and V. Lundblad. Telomere maintenance is dependent on activities required for end repair of double-strand breaks. Curr. Biol. 11:657-660 (1998).
T. Ishikawa, M. Kaniyama, H. Hisatomi, Y. Ichikawa, N. Momiyama, Y. Hamaguchi, S. Hasegawa, T. Narita, and H. Shimada. Telomerase enzyme activity and RNA expression in adriamycin-resistant human breast carcinoma MCF-7 cells. Cancer Let. 141:187-194 (1999).
N. W. Kim, M. A. Piatyszek, K. E. Prowse, C. B. Harley, M. D. West, P. L. C. Ho, G. M. Coviello, W. E. Wright, S. L. Weinrich, and J. W. Shay. Specific association of human telomerase activity with immortal cells and cancer. Science. 266:2011-2015 (1994).
W. E. Wright, J. W. Shay, and M. A. Piatyszek. Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic. Acids Res. 23:3794-3795 (1995).
N. W. Kim and F. Wu. Advances in qualification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic. Acids Res. 25:2595-2597 (1997).
M. Hirose, J. Abe-Hashimoto, H. Tahara, T. Ide, and T. Yoshimura. New method to measure telomerase activity by transcription-mediated amplification and hybridization protection assay. Clin. Chem. 44:2446-2452 (1998).
L. N. Shellner, P. M. Lock, and G. R. Turbett. Simplified method for the telomeric repeat amplification protocol (TRAP). Biotech. 24:726-728 (1998).
S. Gelmini, A. Caldini, L. Becherini, S. Capaccioli, M. Pazzagli, and C. Orlando. Rapid, quantitative nonisotopic assay for telomerase activity in human tumors. Clin. Chem. 44:2133-2138 (1998).
D. Thurnher, B. Knerer, M. Formanek, and J. Kornfehl. Nonradioactive semiquantitative testing for expression levels of telomerase activity in head and neck squamous cell carcinomas may be indicative for biological behaviour. Acta Otolaryngol. 118:423-427 (1998).
M. A. Piatyszek, N. W. Kim, S. L. Weinrich, K. Hiyama, W. E. Wright, and J. W. Shay. Detection of telomerase activity in human cells and tumors. Telomerase repeat amplification protocol (TRAP). Meth. Cell Sci. 17:1-15 (1995).
S. M. Melana, J. F. Holland, and B. G. T. Pogo. Inhibition of cell growth and telomerase activity of breast cancer cells in vitro by 3′-azido-3′-deoxythymidine. Clin. Cancer Res. 4:693-696 (1998).
Y. Y. Wu, A. M. Hruszkewycz, R. M. Delgado, A. Yang, A. O. Vortmeyer, Y. W. Moon, R. J. Weil, Z. Zhuang, and A. Y. Remaley. Limitations on the quantitative determination of telomerase activity by the electrophoretic and ELISA based TRAP assays. Clin. Chim. Acta. 293:199-212 (2000).
D. Sun, C. C. Lopez-Guajardo, J. Quada, L. H. Hurley, and D. D. Von Hoff. Regulation of catalytic activity and processicity of human telometase. Biochemistry 38:4037-4044 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gan, Y., Lu, J., Johnson, A. et al. A Quantitative Assay of Telomerase Activity. Pharm Res 18, 488–493 (2001). https://doi.org/10.1023/A:1011006427733
Issue Date:
DOI: https://doi.org/10.1023/A:1011006427733